TOPIC

/ company

Sinopharm

Sinopharm is a joint venture between state-owned China National Pharmaceutical Group and privately run Fosun Pharmaceutical. The company is the largest wholesaler and retailer of pharmaceuticals and medical devices in China. It produced the first Chinese vaccine against Covid-19.

Chairman / President

Yu Qingming

CEO / Managing Director

Liu Yong

CFO / Finance Director

Li Xiaojuan

Industry

Pharmaceuticals

Website

sinopharm.com

Headquarters address

20th Floor, Building A, International Wealth Center, 129 Xuanwumen West Street, Xicheng District, Beijing, China

Stock Code

SEHK:1099

Year founded

1998

Sinopharm has revived a take-private bid for China Traditional Chinese Medicine Holdings. Photo: Shutterstock

Mergers & Acquisitions

Sinopharm offers to take Hong Kong-listed China-TCM private in US$3 billion deal

A consortium led by state-owned Sinopharm has revived a take-private bid for China-TCM, the Hong-Kong-listed drug maker said on Wednesday, valuing it at US$2.96 billion.

22 Feb 2024 - 9:36AMvideocam

Hong Kong stock market

Hong Kong stocks slide on China property default risk while Sinopharm slumps

5 Sep 2023 - 4:24PMvideocam

Hong Kong stock market

Country Garden is out, Sinopharm in, as Hang Seng Index rebalances

18 Aug 2023 - 11:10PM

Coronavirus China

Covid-19: China’s Sinopharm mRNA vaccine approved for clinical trials

Experimental jab is similar to more effective foreign vaccines and is designed to target the Omicron variant.

20 Jan 2023 - 7:20PMvideocam

Sinopharm’s experimental mRNA jab is similar to more effective foreign vaccines and is designed to target the Omicron variant. Photo: Reuters

Coronavirus China

Merck drug could be available in China by end of next week, Sinopharm says

State-owned drug maker says ‘hundreds of thousands’ of boxes of molnupiravir have arrived and more are being imported.

11 Jan 2023 - 6:15PMvideocam

Coronavirus vaccine

University of Hong Kong, Sinopharm test city’s first Omicron-targeting vaccine

Some 500 Hongkongers have been recruited for clinical trial, out of which 100 have already received the new jabs.

31 May 2022 - 10:50PM

Sinopharm

Sinopharm offers to take Hong Kong-listed China-TCM private in US$3 billion deal

A consortium led by state-owned Sinopharm has revived a take-private bid for China-TCM, the Hong-Kong-listed drug maker said on Wednesday, valuing it at US$2.96 billion.

Hong Kong stocks slide on China property default risk while Sinopharm slumps

Country Garden is out, Sinopharm in, as Hang Seng Index rebalances

Covid-19: China’s Sinopharm mRNA vaccine approved for clinical trials

Experimental jab is similar to more effective foreign vaccines and is designed to target the Omicron variant.

Merck drug could be available in China by end of next week, Sinopharm says

State-owned drug maker says ‘hundreds of thousands’ of boxes of molnupiravir have arrived and more are being imported.

University of Hong Kong, Sinopharm test city’s first Omicron-targeting vaccine

Some 500 Hongkongers have been recruited for clinical trial, out of which 100 have already received the new jabs.

Fourth Sinopharm shot won’t boost protection against Omicron, study finds

Sun Yat-sen University research, which has not been peer-reviewed, suggests immune response cannot be endlessly boosted and there will be a ‘turning point’ after repeated vaccination.

South African health regulator registers Sinopharm Covid-19 vaccine

Sahpra said the authorisation was ‘based on acceptable safety, quality and efficacy data’ from the July-December period.

Sinopharm protein-based booster stronger against Omicron than earlier shot

Study authors caution that it’s still not clear how long the effects of the boosters will last.

Sinopharm and Sinovac shots may fend off severe Omicron illness: WHO

Antibodies from the vaccines decline but T-cells still appear to go into action, health body’s incident manager says.

Covid-19 booster from China’s Sinopharm is weaker against Omicron, study finds

The jab shows significantly weaker neutralising activity against the variant than against an older strain, researchers say.

Omicron evades protection from 2 doses of Sinopharm vaccine: study

Researchers from the University of Washington and Humabs BioMed investigated how Omicron might escape immunity from past infections or vaccination.

Experts say third shot needed for elderly given Sinovac or Sinopharm

SAGE says extra dose is not a booster shot but an extension of the main vaccination course.

Chinese vaccine safe for children as young as 3, says study

The data was released as a fresh cluster of cases in primary school children has intensified the debate about vaccinating under-12s.

Sinopharm is working on an updated Covid-19 vaccine for variants

It is being developed to provide protection against Delta and Beta strains, and clinical trials of a booster shot are also under way, CNBG vice-president says.

UAE approves China’s Sinopharm shot for children as young as 3

Emergency use authorisation comes after clinical trials and extensive evaluations, just weeks following China’s expansion of its vaccination drive to under-18s.

Vietnam approves Sinopharm’s vaccine, but will people take it?

Only 1 per cent of Vietnam’s population has received at least one vaccine dose, trailing the efforts of poorer neighbours like Cambodia and Laos.

Sinopharm finally publishes Covid-19 vaccine trial data

Interim phase 3 results suggest two products have efficacy above 70 per cent for symptomatic cases but there is little data on elderly and vulnerable groups.

Immunity induced by Sinopharm jab questioned after UAE offers booster shots

United Arab Emirates and Bahrain say they will provide a third shot of the Chinese Covid-19 vaccine to people who completed the two-dose regimen six months ago.

UAE to offer third dose to recipients of China’s Sinopharm vaccine

The United Arab Emirates appears to be the first country worldwide to formally introduce such booster shots; move comes amid concerns about insufficient antibody response.

Opinion | WHO’s Sinopharm approval opens the door for China’s vaccine industry

China should work with the WHO and other international entities to make Covax and similar schemes a success. Being active in multilateral channels can help overcome geopolitical hurdles and ensure access to more foreign markets in the future.

WHO gives emergency approval to China’s Sinopharm Covid-19 vaccine

The green light given to Sinopharm comes more than four months after the WHO handed out its first emergency use listing for a Covid-19 vaccine to US pharmaceutical company Pfizer and German company BioNTech.

Indonesia approves Sinopharm jab; guest catches virus on Japan cruise ship

After Sinovac and AstraZeneca, Sinopharm is the third company to have its vaccine approved by Indonesia.

China picks UAE as Sinopharm production hub

Gulf Pharmaceutical Industries PSC said on Sunday it signed a contract to start manufacturing the vaccine from April.

Sinopharm profit rises, ready to meet China’s 500 million Covid-19 jabs goal

Sinopharm Holding was ready to deliver the Covid-19 vaccines needed to meet Beijing’s target of more than 500 million vaccinations by June this year, its president said.

Pakistan receives 500,000 Sinopharm shots from China

Elsewhere, Taiwan will form its first travel bubble of the pandemic with the tiny Pacific nation of Palau, and Japan is to lift a state of emergency in the Tokyo area.

Covid-19 vaccines made by China’s Sinopharm, CanSino release efficacy data

Wuhan unit of state-owned Sinopharm, whose first vaccine was approved for general use in December, says second product has an efficacy rate of 72.5 per cent.

Hungary starts using Chinese Covid-19 vaccine in EU first

‘This is an important day as we begin inoculations with the Chinese vaccines,’ Prime Minister Orban says.